VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:VNDA

<< 이전 1 2 3 4 5 6 7 8 9 10 11 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/17	22:02	PR Newswire (US)	Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	23:25	AllPennyStocks.com	Biotech Catches Major Premarket Bid Following FDA Approval	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	07:10	PR Newswire (US)	Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/08	06:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/06	21:00	PR Newswire (US)	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11:10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11:06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06:32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/17	06:31	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	21:19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	06:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	06:02	PR Newswire (US)	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/06	06:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/05	22:00	PR Newswire (US)	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/01	06:30	PR Newswire (US)	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/01/31	23:00	PR Newswire (US)	Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/01/31	02:35	PR Newswire (US)	Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024	NASDAQ:VNDA	Vanda Pharmaceuticals Inc